Уколы лаеннек: Ваш браузер устарел

Лаеннек – инструкция по применению препарата, отзывы, цена, аналоги Знаете ли вы, что:

Существуют очень любопытные медицинские синдромы, например, навязчивое заглатывание предметов. В желудке одной пациентки, страдающей от этой мании, было обнаружено 2500 инородных предметов.

74-летний житель Австралии Джеймс Харрисон становился донором крови около 1000 раз. У него редкая группа крови, антитела которой помогают выжить новорожденным с тяжелой формой анемии. Таким образом, австралиец спас около двух миллионов детей.

Кроме людей, от простатита страдает всего одно живое существо на планете Земля – собаки. Вот уж действительно наши самые верные друзья.

Когда влюбленные целуются, каждый из них теряет 6,4 ккалорий в минуту, но при этом они обмениваются почти 300 видами различных бактерий.

Если бы ваша печень перестала работать, смерть наступила бы в течение суток.

Согласно исследованиям, женщины, выпивающие несколько стаканов пива или вина в неделю, имеют повышенный риск заболеть раком груди.

Печень – это самый тяжелый орган в нашем теле. Ее средний вес составляет 1,5 кг.

По статистике, по понедельникам риск получения травм спины увеличивается на 25%, а риск сердечного приступа – на 33%. Будьте осторожны.

Люди, которые привыкли регулярно завтракать, гораздо реже страдают ожирением.

Стоматологи появились относительно недавно. Еще в 19 веке вырывать больные зубы входило в обязанности обычного парикмахера.

Для того чтобы сказать даже самые короткие и простые слова, мы задействуем 72 мышцы.

Кровь человека «бегает» по сосудам под огромным давлением и при нарушении их целостности способна выстрелить на расстояние до 10 метров.

Если улыбаться всего два раза в день – можно понизить кровяное давление и снизить риск возникновения инфарктов и инсультов.

Самая высокая температура тела была зафиксирована у Уилли Джонса (США), который поступил в больницу с температурой 46,5°C.

Средняя продолжительность жизни левшей меньше, чем правшей.

Остерегайтесь подделок препарата Лаеннек

Всем заинтересованным лицам

Уважаемые господа!

ООО Медицинская Корпорация «РАНА» как эксклюзивный дистрибутор лекарственного препарата для медицинского применения «Лаеннек» производства компании Japan Bio Products Co., Ltd.» (JPB Со., Ltd.) (Япония) в форме раствора для инъекций (в ампулах по 2 мл) и держатель регистрационного удостоверения данного препарата, сообщает, что с февраля 2019 г. производитель препарата вводит в обращение препарат (№ 10 и № 50) с новым оформлением; соответствующие изменения в документы, содержащиеся в регистрационном досье на зарегистрированный лекарственный препарат, согласованы и зарегистрированы Министерством Здравоохранения РФ 08.10.2018 г.

В соответствии с п. 9 ст. 30 Федерального закона от 12 апреля 2010 г. № 61-ФЗ «Об обращении лекарственных средств» обращение лекарственного препарата с предшествующим оформлением допустимо до истечения его срока годности, соответственно, в течение какого-то периода времени на территории РФ в обращении будет лекарственный препарат как с новым оформлением, так и с предшествующим.

Гарантиями качества и безопасности препарата является приобретение его только у ООО Медицинская Корпорация «РАНА» и его официальных представителей, информация о которых представлена на сайтах компании — http://laennec.ru, а также наличие фирменной русифицированной упаковки, специально разработанной для поставок и продаж на территории РФ и утвержденной МИНЗДРАВОМ РОССИЙСКОЙ ФЕДЕРАЦИИ, наличие защитной голограммы и контроля вскрытия, идентификационного номера произведенной серии препарата (указан на обратной стороне упаковки, тот же номер обозначен на каждой ампуле) и информации о дистрибуторе (обязательное присутствие логотипа RHANA). Изображения оригинальной продукции и средств ее идентификации и защиты (как с новым оформлением, так и с предшествующим) можно проверить на сайте компании — http://laennec.ru, указав номер серии препарата.

Предлагаемые к продаже препараты в нерусифицированных упаковках, препараты производства не завода «Japan Bio Products Co., Ltd.» (JPB Со., Ltd.) (Япония) являются, как минимум, нелегальными и контрафактными. Ни компания производитель, ни её эксклюзивный дистрибутор не несут ответственности за качество и безопасность данных препаратов.

Будьте осторожны при приобретении лекарственных препаратов.

Кроме того, поскольку исключительное право на использование товарного знака ЛАЕННЕК на территории Российской Федерации в отношении, в том числе, соответствующих лекарственных препаратов и медицинских услуг, принадлежит ООО Медицинская Корпорация «РАНА» (свидетельство на товарный знак № 552870), предложение к продаже, продажа и использование для оказания услуг третьими лицами препаратов с использованием обозначения ЛАЕННЕК или сходных с ним обозначений (LAENNEC, LAENEC, LAENNEK, ЛАЕНЕК и т.д.) без соответствующего разрешения является нарушением исключительных прав на товарный знак, за которое законодательством предусмотрена ответственность, в том числе уголовная. Во избежание претензий о нарушении прав на товарный знак избегайте приобретения и использования контрафактных препаратов.

О нас детальная

ИНСТРУКЦИЯ
по применению лекарственного препарата для
медицинского применения
ЛАЕННЕК

Регистрационный номер: П №013851/01

Торговое название: Лаеннек

Лекарственная форма: раствор для инъекций

Состав В 2 мл препарата содержится ­112 мг гидролизата плаценты человека, вода для инъекций, корректор рН (натрия гидроксид или кислота хлористоводородная).

Описание Прозрачная жидкость от светло-желтого до коричневого цвета с характерным запахом.

Фармакотерапевтическая группа Иммуномодулирующее и гепатопротекторное средство.

Код АТХ: L03, А05ВА

Фармакологические свойства Лаеннек проявляет иммуномодулирующие свойства за счет способности стимулировать гуморальный иммунитет и повышать функциональную активность фагоцитов и естественных киллеров; увеличивает бактерицидную активность лейкоцитов периферической крови, проявляющуюся в их способности уничтожать захваченный возбудитель. Цитокины, входящие в состав препарата, активизируют метаболическую и надзорную функции клеток кожи.

Биологически активные вещества, находящиеся в гидролизате, стимулируют регенерацию (пролиферацию) гепатоцитов, проявляют дезинтоксикационные свойства, снижают отложение липидов и холестерина в печеночных клетках, повышают активность тканевого дыхания, активизируют обмен веществ в печени, снижают интенсивность развития соединительной ткани в печени.

Показания к применению Препарат применяется в комплексной терапии следующих заболеваний: хронический рецидивирующий герпес, атопический дерматит среднетяжелого и тяжелого течения (в том числе, осложненный). В виде монотерапии при хронических заболеваниях печени: стеатогепатитах (алкогольной, метаболической и смешанной этиологии).

Противопоказания Гиперчувствительность, детский возраст, беременность, период лактации.

С осторожностью С осторожностью следует применять препарат у пациентов, страдающих поливалентной аллергией на лекарственные препараты, а также у лиц пожилого возраста.

Способ применения и дозы

• При хроническом рецидивирующем герпесе и атопическом дерматите: внутривенное капельное введение: 10 мл (560 мг гидролизата плаценты) препарата (5 ампул) растворяют в 250 -500 мл 5% раствора декстрозы или физиологического раствора и вводят через локтевую вену в течение 1,5 — 2 часов. Инъекции проводят 3 раза в неделю с интервалом в 2 дня. Курс лечения 10 инъекций.
• При хронических заболеваниях печени: стеатогепатитах (алкогольной, метаболической и смешанной этиологии): внутримышечно: по 2 мл в сутки (112 мг гидролизата плаценты). В зависимости от тяжести заболевания частота инъекций может быть увеличена до 2 -3 раз (до 6 мл) в сутки; внутривенное капельное введение: 10 мл (560 мг гидролизата плаценты) препарата (5 ампул) растворяют в 250 -500 мл 5% раствора декстрозы или физиологического раствора и вводят через локтевую вену в течение 1,5 — 2 часов. Инъекции проводят ежедневно. Курс лечения 2- 3 недели.

Побочное действие Отмечается у 3,7% больных.

Клинически значимые нежелательные реакции.

Возможны аллергические реакции, в том числе анафилактический шок.

Другие нежелательные явления

Болезненность в месте инъекции	2.56%
Аллергические реакции (покраснение, зуд кожи)	0.37%
Онеменение в месте инъекции	0.37%
Гинекомастия (причинно-следственная связь с введением препарата не установлена)	0.37%

Передозировка: в настоящее время о случаях передозировки Лаеннека не сообщалось.

Взаимодействие с другими лекарственными средствами При смешивании Лаеннека с другими препаратами, являющимися сильными основаниями (рН выше 8.5), в результате фармацевтического взаимодействия его активность снижается. Сведения о каких-либо других клинически значимых взаимодействиях Лаеннека до настоящего времени отсутствуют.

Применение в период беременности и грудного вскармливания Применение препарата в период беременности и грудного вскармливания противопоказано.

Применение препарата у детей Исследования по безопасности применения Лаеннека у недоношенных детей, новорожденных грудных и несовершеннолетних детей не проводились. Применение у детей не рекомендуется.

Применение препарата у пожилых Согласно имеющимся в настоящее время данным пожилой возраст не является противопоказанием для назначения Лаеннека. Тем не менее, поскольку физиологические функции у пожилых людей ухудшаются, применение препарата должно проводиться под тщательным контролем.

Сведения о возможном влиянии на способность управлять транспортными средствами, механизмами Влияние на способность управлять транспортными средствами, механизмами не установлено.

Форма выпуска Раствор для инъекций. По 2 мл в ампулах темного стекла гидролитического класса 2. Каждая ампула имеет пятно белого цвета, обозначающее место надлома ампулы. По 10 или 50 ампул в картонную пачку с перегородками из картона с инструкцией по применению.

Срок годности 3 года. Не применять по истечении срока годности, указанного на упаковке.

Условия хранения При температуре от +18 до +25° С в защищенном от света месте.
Хранить в местах, недоступных для детей.

Условия отпуска из аптек По рецепту.

Производитель Джапан Био Продактс Ко., Лтд, 1-44-4, Томигая Шибуя-ку, Токио, 151-0063, Япония.

Владелец регистрационного удостоверения/организация, принимающая претензии/ Эксклюзивный дистрибьютор в России ООО Медицинская Корпорация «РАНА», Россия, 123242, г. Москва, ул. Зоологическая, д.22, тел.: +7(499) 766-27-27

90000 Buy Laennec 2 ml X 50 vials for anti-aging and skin tightening with placenta hydrolysate online from Japan 90001 90002 Basic information about Laennec 90003 90004 90005 Official manufacturer 90006: JBP Co Ltd, Japan 90007 90004 90005 Active ingredient: 90006 human placenta hydrolysate. 90007 90004 90005 Selling start 90006: July, 1979, in Japan after clinical trials (conducted throughout the Japan in 124 cases).90007 90004 90005 Official Code 90006 in Japan: 3259601A1024 90007 90004 Laennec is officially registered in USA, South Korea, China, Russia and NIS countries. 90007 90004 90023 90005 Clinically significant adverse reactions and Contraindications 90006 90026: allergic reactions are possible. 90007 90004 90005 FREE WORLDWIDE SHIPPING! WE SHIP TO YOUR COUNTRY! 90006 90007 90004 90005 BEST OFFER 789 USD FOR BANK PAYMENT ONLY — CONTACT US NOW! 90006 90007 90002 Related Articles about Laennec 90003 90004 Where can I get detailed information about clinical studies of laennec? Is Laennec a really effective medicine? What differs Laennec from similar Japanese placenta injections? If you’d like to know answers for these questions, our articles below may help you.90007 90002 Clinical studies of Laennec 90003 90004 Clinical trials were conducted throughout Japan. As a result, positive effects on blood counts such as GOT and GPT were recognized. Furthermore, Laennec was used in a number of liver and lung diseases. Similarly, it showed high regeneration and recovery effects. Studies were conducted at 95% intervals, for a more accurate effect. In addition, doctors conducted placebo tests to achieve even more accurate results. Side effects identified during the tests include allergies in 3.7% of patients. In less than one percent, itching and numbness were observed. But a clear connection between the injection and these symptoms has not been scientifically established. It is highly not recommended to use the medicine during pregnancy and breastfeeding. 90007 90004 Laennec appears in a variety of publications and scientific studies of medical subjects in Japan. For instance, the medical effect of Laennec in the treatment of the liver was investigated by the doctor Ueda Hideo.His research Acta hepatologica Japonica Vol.15 (上 田英雄 肝 臓, vol.15 162 тисяча дев’ятсот сімдесят чотири (click here to follow) shows the positive effects of applying Laennec during clinical trials. Besides that, Dr. Sakamoto Koji (坂 本 浩 二) performed researches on anti -age therapy and treatment of diseases of internal organs using cell regeneration in the University of Tokyo Medical Journal (東京 医科大学 雑 誌). Dr. Sakamoto paid special and deep attention to detailed clinical research on side effects before launching Laennec in Japan — in the issue of 東京 医科大学 雑 誌, vol.33,271 (1975) as well as 東京 医科大学 雑 誌, vol.31,829 (1973) and in 東京 医科大学 雑 誌, vol.32,351 (1974).90007 90002 Dosage and administration for Laennec 90003 90004 In chronic recurrent herpes and atopic dermatitis, Laennec is injected via IV. 10 ml (560 mg of placental hydrolyzate) of the medicine (5 vials) are dissolved in 250-500 ml of 5% dextrose solution or saline and injected through the ulnar vein for 1.5 -2 h. Injections are carried out 3 times a week with an interval of 2 days. Over all, the course of treatment includes 10 injections. 90007 90004 90007 90004 In chronic liver diseases (steatohepatitis, alcoholic, metabolic, and mixed etiology), the drug is administered intramuscularly at 2 ml / day (112 mg of placental hydrolyzate).Depending on the severity of the disease, the frequency of injections can be increased up to 2-3 times (6 ml) / day. Also the medicine can be injected via IV. 10 ml (560 mg of placentae hydrolyzate) of the drug (5 ampoules) are dissolved in 250-500 ml of 5% dextrose solution or saline and injected through the ulnar vein for 1.5-2 hours. Injections are carried out daily. In that case, the course of treatment is 2-3 weeks. 90007 90004 90007 90056 BEWARE OF FALSE LAENNEC FROM KOREA AND CHINA! 90057 90004 It is very important to identify original Laennec from Chinese and Korean fake copies.Original Laennec is shipped only from Japan (from hospital). And it is never sold on domestic market, because that’s a violation of Japan Law. 90007 90004 90005 Expiration date is 1 year. Laennec manufactured in Japan differs from placenta hydrolysate manufactured in other countries. It contains tried-and-true components, it has better effec. But its shelf life is 1 year only. 90006 90007 90004 PLEASE PAY ATTENTION! 90007 90004 Expiry date is less than 1 year (about 7-9 months).One box of 50 vials is for 5-6 months course. Apply one vial every 2 days for 2 months, then repeat in 1 — 1,5 months. — 90007 90004 Product is shipped directly from Japan only. 90005 WE SHIP IN 5-7 BUSINESS DAYS. 90006 90007 90002 Laennec from Japan: Dummy or Effective medicine? 90003 90004 Certainly, clients often write us different questions about Laennec. How to get original Japanese Laennec? How to distinguish a fake and original product? And, especially recently, many people asked us whether Laennec will be effective in case of this or that disease.Some people believe it might be effective in treating cancer, oncology, stroke, kidney failure, diabetes and so on. We feel very much concerned about it because those misbeliefs might be dangerous. Where do you, dear customers, take these data (about the potential effectiveness of the Laennec in case of oncology, etc.)? We will do our best to clarify the situation once and for all. 90007 90002 What Laennec is effective for? 90003 90004 Please, remember, the Japanese Laennec is effective for the following deseases and conditions.First, liver diseases, including hepatitis. But severe cases requirs additional treatment and other medicines. Second, for skin diseases, including psoriasis, except for severe cases). Third, for the purpose of rejuvenating and antiaging therapy. The last purpose is not certified by medical supervisory authorities in number of countries. However, it has been fully proved and confirmed in Japan and the USA. The efficacy of placental preparations has been also proven in Korea, where some of JBP products are produced.90007 90002 How to identify genuine Laennec from Japan? 90003 90004 Japanese-made Laennec can be purchased only in Japan. You can not purchase it neither in China, nor in the Philippines or in Thailand! Unfortunately, fakes exist even in Japan. For instance, they are sold from companies without a license or through net auctions like Ebay. On this product page, there is a complete guide on how to distinguish the original Japanese Laennec. Customers sent us photos of goods purchased in other countries.Ampoules have different lengths, shape, heterogeneous colour etc. Prints on the packaging are dirty, leaving stains and marks. But even this is not the main point though a sufficient one. There is a simple and reliable way to distinguish a true Laennec from Japan. 90007 90056 How to identify genuine Laennec from Japan? 90057 90004 Pay attention to the packaging and the ampoules. On the packaging there is a unique three-dimensional volumetric code, which is hard enough to make and almost impossible to copy.Furthermore, on each ampoule of the Laennec there are two long numeric codes. These two codes are special labeling as required by the Japanese Medicines Act dated year 2008. The upper code is the sales lot code. And the lower code is the code of the batch of pharmaceutical raw materials used for production. In other words, one code is responsible for the sale, the second for the manufacture. 90007 90056 How to apply Laennec in right way? 90057 90004 Applying the medicine should be carried out strictly under the supervision of a specialist or doctor.Base dosages can be found on this page. The product can be used intramuscularly, intravenously and for mesotherapy. Pay attention, if there are allergic reactions or any uncomfortable sensations, the application of the Laennec should be stopped immediately. HUMAN PLACENTA. ANTI-AGING, WHITENING, MOISTURIZING 100% human Placenta Laennec. Original, directly from Japan. From Maker and official distributor. 2 ml * 50 pcs. 90007 90056 CLICK HERE AND ASK ANY QUESTION! GET ANSWER IN 24 HOURS 90057 90056 CLICK TO CHECK OUR GUARANTEES & CUSTOMER REVIEWS 90057 90004 90005 WORLDWIDE SHIPPING.FIXED RATE AS LOW AS $ 19 PER PARCEL 90006 90007 90002 How to identify original product? 90003 90004 90103 1. Original JBP package for domestic market. 90104 90007 90004 90107 90007 90004 2. Made in Japan marking on the side of original package. ( «Manufactured and Distributed by JBP Japan»). 90007 90004 90112 90007 90004 3. Expiry date and bar code. At the bottom there is a serial number of product. Specific 3D bar code with series and number (on the picture old code is shown, we always ship goods with 8-9 months ‘expiry date that is enought for full course.Box has pharma serial number and sales lot serial nuber (japanese control system). We covered series for privacy reasons. 90007 90004 90117 90007 90004 4. Ampoules of correct shape with serial number and bar code on every vial. 90007 90004 90122 90007 90004 90005 To protect privacy of our distributor we have hidden bar codes and serial number! 90006 90007 90004 5. For all laennec with expiration date of 2019.07 and further there is additional sticker added to package for protection reasons, as showm below.90007 90004 90131 90007 90002 Laennec is effective for: 90003 90004 90005 Common ailments 90006 90007 90139 90140 General fatigue 90141 90140 Stiffness of shoulders 90141 90140 Anemia 90141 90140 Raynaud disease 90141 90148 90004 90005 Male and female sexual sphere 90006 90007 90139 90140 Prostatic hypertrophy 90141 90140 Menopause and Andropause (male menopause) 90141 90140 Dysmenorrhea 90141 90140 Ovarian Dysfunction 90141 90140 Frigidity 90141 90148 90004 90005 Alimentary system 90006 90007 90139 90140 Chronic constipation 90141 90140 Gastroptosis 90141 90140 Gastric ulcer 90141 90140 Dyspepsia 90141 90140 Hepatitis 90141 90140 Liver cirrhosis 90141 90148 90004 90005 Skin 90006 90007 90139 90140 Urticaria (hives) 90141 90140 Eczema 90141 90140 Melasma 90141 90140 Keloid scar 90141 90140 Lupus 90141 90148 90002 100% HUMAN PLACENTA EXTRACT 90003 90004 100% Human Placenta Extract (HPE) is proven to be beneficial to human body.Japanese government acknowledged it as an alternative medicine for anti-aging program. Also, the American National Agency for Food and Drug did agree with that. Naturally, HPE is more compatible and harmless for humans rather than Animal Placenta Extract. Certified in Japan, USA and Korea, this is currently one of the most effective and reliable injectable medicines. 90007 90056 90005 Official Japanese Certificate 90006 90057 90004 90208 90007 90004 Delivery time — 10-15 days after the order.Order is processed at beauty clinic, Niigata prefecture. 90007 90004 90005 PRICE 789 USD FOR BANK PAYMENTS ONLY — CONTACT US NOW! 90006 90007 90004 90005 ORDER 3 BOXES BY BANK, GET 450 USD (739 USD PER BOX) DICSOUNT NOW! 90006 90007 90004 90005 You can order 10 vials here (click) 90006 90007 90004 E-mail us your name and address, we shall issue an invoice. You will purchase Original Laennec from Japan for 789 usd! When purchased online, the price is 889 usd.90007 90004 90005 FREE WORLDWIDE DELIVERY! WE SHIP TO YOUR COUNTRY! 90006 90007 .90000 Japan Bio Products Co., Ltd. 90001 90002 Laennec is the ethical drug manufactured with JBP’s unique technologies. 90003 90004 Laennec is the ethical drug manufactured with JBP’s unique technologies for effective extraction of variety of growth factors, cytokines, and other physiologically active substances from the human placenta. For instance, HGF (hepatocyte growth factor) promotes the proliferation of hepatic parenchymal cells for recovery of a damaged liver.Our product safety is ensured by the most rigid safety measures among existing scientific standards. 90005 90004 90007 Warning: 90008 90007 As LAENNEC Injection is an ethical drug, JBP has never sold it on Internet. 90008 90005 90012 90013 90014 90015 90016 90015 Ingredients 90016 90015 Content 90016 90015 Remarks 90016 90023 90014 90015 Active ingredient 90016 90015 Water-soluble substance of a product of enzymatic human placenta 90016 90015 112 mg 90016 90015 Ingredient extracted from human placenta 90016 90023 90014 90035 Inactive ingredients 90016 90015 Pepsin 90016 90015 Trace 90016 90015 Gastric mucosal extract 90016 90023 90014 90015 Lactose 90016 90015 0.6 mg 90016 90015 — 90016 90023 90014 90015 pH adjuster 90016 90015 q.s. 90016 90015 — 90016 90023 90060 90061 90004 90007 Description 90064 90008 This product is a light yellow-brown or yellow-brown clear liquid with a distinctive odor. The pH level ranges from 5.5 to 6.5 and the osmotic pressure ratio (to physiological saline) is approximately one. 90005 90004 90007 Indications 90064 90008 Improvement of hepatic function in chronic hepatic disease.90005 90004 90007 Dosage and administration 90064 90008 The normal adult dose is a 2 ml subcutaneous or intramuscular injection once daily. According to symptoms, the dose can be increased to 2 or 3 times daily. 90005 90004 90007 Packaging 90064 90008 2 ml 50 ampoules 90005 90002 Cautions for use ** 90007 90008 90003 90004 90007 1. Careful Administration 90064 90008 LAENNEC should be administrated with care in patients predisposed to allergies. 90005 90004 90007 2. Important Basic Cautions 90064 90008 This product is manufactured from the extract of human placenta delivered full-term in Japan.In order to screen each donor, a complete medical history, interviewing such as a history of travel and serologic testing for viruses, bacteria and infection are performed, after nucleic-acid testing (NAT) to meet with requirements for HBV-DNA, HCV- RNA and HIV-1-RNA is carried out. In addition, it has been confirmed that high-pressure steam sterilization for 20 minutes at 121 ° C during the manufacturing process is effective in inactivating various viruses such as HIV etc. Furthermore, although in the product test, the nucleic-acid test meets with requirements for HBV-DNA, HCV-RNA, HIV-1-RNA, HTLV-DNA, and parvovirus B19-DNA, patients should be made aware of the following points during administration: To date, the transmission of infection, such as variant Creutzfeldt-Jakob disease (vCJD), by administration of this product in Japan or other countries has not been reported.However, although safety measures are taken to prevent infection during the manufacturing process, it is theoretically impossible to fully eliminate the risks of infection transmission originating in a human placenta used as raw material. While safety measures during the manufacturing process to prevent infection, as well as confirmation of the necessity of treatment for the disease before administration are carried out, doctors should explain to patients and try to have them understand that when human placenta is used as the raw material of a product, the risk of infection can not be fully ruled out.90005 90004 90007 3. Drug Interactions 90064 90008 When this product is directly mixed with a strong base preparation of pH 8.5 or more, attenuation of pharmacological activity has been reported. 90064 No coadministration with this product resulting in the enhancement or attenuation of the pharmacological effect of this product or concomitant drugs, appearance of adverse reactions, or aggravation of disease has been reported. 90005 90004 Adverse reactions or patients who were suspected to have suffered adverse reactions to this product were reported in a total of 10 (3.7%) of the 273 patients selected for safety evaluation in the clinical study performed during implementation of reevaluation of the drug efficacy. The most frequently observed adverse reactions were injection site pain in 7 patients (2.6%), hypersensitivity (such as rash, fever, and itching) in 1 patient (0.4%), injection site indurations in 1 patient (0.4%), and gynaecomastia in 1 patient (0.4%). The causal relationship between gynaecomastia and this product is unknown. 90064 No abnormal changes in laboratory values ​​were observed.90104 1) 90064 90106 • Clinically significant adverse reactions 90064 ** Shock (incidence unknown): 90064 Since this product is a protein / amino acid preparation derived from human tissue, this product may cause a shock. If any signs of abnormality are observed, the drug should be discontinued immediately, appropriate measures should be taken and the condition should be monitored fully. 90064 • Other adverse reactions (in descending order of occurrence) 90005 90111 90013 90014 90015 Injection site pain 90016 90015 2.56% 90016 90023 90014 90015 Sensitivity (rash, fever, itching etc.) 90016 90015 0.37% 90016 90023 90014 90015 Injection site indurations 90016 90015 0.37% 90016 90023 90014 90015 Gynaecomastia 90016 90015 0.37% 90016 90023 90060 90061 90004 90007 4. Use in the Elderly 90064 90008 From clinical data and present use, no particular caution is needed in the administration of this product to the elderly.However, since elderly patients often have reduced physiological function, it should be administrated with care. 90005 90004 90007 5. Use during Pregnancy. Delivery or Lactation 90064 90008 In reproductive development toxicity experiments on animals, including teratogenicity, this product can be considered not to have such toxicity. 90104 2) 90106 90005 90004 90007 6. Pediatric use 90064 90008 The safety of this product in premature infants, newborns, infants, toddlers or children has not been established due to insufficient clinical data.90005 90004 90007 7. Overdosage 90064 90008 Overdosage of this product and the resulting efficacy or safety have not been established (Due to insufficient clinical data). 90005 90004 90007 8. Precautions for Use 90064 90008 Injection site: 90064 In order to avoid any effect on tissue or nerves, the product should be injected subcutaneously or intramuscularly taking the following precautions: 90064 a) For the injection site, to avoid nerve pathways, it should be administrated with care.90064 b) In the case of repeated injections, avoid injecting into the same site by alternating on the left and right side etc. 90064 c) If intense pain or regurgitation of blood is observed, the needle should be removed immediately, and injected into a different site. 90064 Opening the ampoule: 90064 When opening the ampoule, it is preferable to wipe the part to be cut with an ethanol sponge before opening it. 90005 90004 90005 90002 Pharmacokinetics 90003 90004 The bioactive ingredients of LAENNEC are extracted from human placenta, and the primary pharmacological effects of this product can not necessarily be attributed to a single substance or ingredient.Therefore, evaluation of the pharmacokinetics (absorption, distribution, metabolism, and excretion) of this product has not been established. 90005 90004 90005 90002 Clinical studies 90003 90004 90007 1. Double blind comparison to chronic hepatitis and hepatic cirrhosis 90104 1) 90064 90106 90008 In a double-blind crossover study of 124 patients in Japan on the effects of this product on chronic hepatitis and hepatic cirrhosis, administration of this product improved serum transaminase (GOT, GPT) levels significantly (see figures below).90005 90004 Efficacy to GOT 90064 90005 90004 Efficacy to GPT 90064 90005 90004 Summary of drug-efficacy 90064 [(A) Items having a tendence to decrease or increase significantly by Laennec] 90005 90004 Data on pharmacological reevaluation 90064 Summary of drug-efficacy 90064 [(B) Items having a tendence to decrease or increase significantly by Placebo] 90005 90004 90007 2. Action on HCV-RNA levels 90104 3) 90064 90106 90008 Twenty subjects of two-agent combination therapy only with Stronger Neo-Minophagen C and Acelart were performed in the past and negativation neither of C100-3 antibody nor HCV-RNA was admitted in them.In three-agent combination therapy with Laennec added, two negative cases of serum HCV-RNA levels were admitted. 90005 90004 90005 90002 Pharmacology 90003 90004 90007 1. Stimulatory effects of hepatic reproduction 90104 4), 5) 90064 90106 90008 After 70% of livers in healthy rats was resected, time comparisons of liver weight to the control groups resulted in significant stimulation of hepatic reproduction in the Laennec groups. 90005 90004 90007 2. Stimulatory effects of cellular DNA synthesis 90104 4) 90064 90106 90008 Compared to control groups, in vivo experimental system using primary culture rat hepatocytes, the DNA-synthesis accelerator activity was observed in 2 μL / ml-administrated groups.That accelerator activity was equivalent to 10 pM of rHGF. The liver tissue in vivo experimental system using rats with acute hepatitis by ANIT was stained and the result of evaluation of the rate of hepatocyte nucleus in DNA synthesis period showed significant accelerator of DNA synthesis compared to the control groups. 90005 90004 90007 3. Inhibitory effects of experimental liver injury 90104 4), 6) 90064 90106 90008 Compared to control groups, in vivo experimental system using rats with acute hepatitis by ANIT, the liver cytosolic enzymes in serum (GPT, ALP, LAP and g -GTP) and the bilirubin levels significantly degreased in the Laennec groups.90064 In addition, compared to control groups, in vivo experimental system using rats with acute hepatitis and chronic hepatitis by CCI4, the liver cytosolic enzymes in serum (GPT, GOT) significantly degreased and histopathologically improved liver disorder in the Laennec groups. 90005 90004 90007 4. Anti-fatty liver action 90104 7) 90064 90106 90008 A 5-day subcutaneous injection of 1.2 ml / kg of this product in rats suffering from acute hepatic disorder with CCI4 resulted in a significant decrease in hepatic weight to body weight as compared with the control groups.Furthermore, total hepatic lipids and total hepatic cholesterol decreased significantly in the 3.6 ml / kg dose groups, and hepatohistological findings to support such results were seen and the body weight was realized. 90064 After pretreatment of acute hepatic disorder with CCI4, there were no significant differences with regards to biochemical findings between the control groups and when 5-day repeated, subcutaneous administration of 1.2 ml / kg of this product was performed. However, in the 3.6-ml / kg dose groups, maintenance of lobular structure was better than the control groups with regards to hepatohistological findings.90005 90004 90007 5. Absorption accelerated activity on interstitial connective tissue 90104 8) 90064 90106 90008 This product exhibited inhibitory action of fibroplasias in rat liver due to 12-week repeated administration of CCI4, and it was confirmed histologically that once multiplied, interstitial connective tissues were absorbed. 90005 90004 90005 90002 Physicochemistry 90003 90004 This product is human-placental extract, and contains various biological active substances. However, the active ingredients of this agent can not be specified as a single substance or several sorts of substances.90005 90004 90005 90002 Precautions for handling * 90003 90004 This product corresponds to a specialized biological product. Therefore, when this product is administrated, the product name, manufacturing No., date of administration (or prescription), name and address of patients should be reported and stored for at least 20 years in accordance with the order issued by the Japanese Ministry of Health, Labour and Welfare. This product should be used with attention to the point that the indication of this product is «improvement of hepatic function in chronic liver disease».90005 90004 90005 90004 90007 References 90064 90008 1) Ueda H. et al .: Kanzo (Liver), vol.15, 162, 1974 90064 2) Taniguchi H. et al .: data on file in Japan Bio Products Co. Ltd., 1985-1991 90064 3) Takami T .: Kiso to Rinsho, vol.30, 3549, 1996. 90064 4) Liu K. et al .: Yakuri to Rinsho, vol.5, 2187, 1995 90064 5) Sakamoto K . et al .: Journal of Tokyo Medical University, vol.33, 271, 1975 90064 6) Nakayama S. et al .: Folia Pharmacologica Japonica, vol.94, 289, 1989 90064 7) Sakamoto K. et al.: Journal of Tokyo Medical University, vol.31, 829, 1973 90005 .90000 Buy Laennec essence 2 ml * 50 vials for Anti-aging online at sale price 90001 90002 90003 FREE WORLDWIDE SHIPPING! WE SHIP TO YOUR COUNTRY! 90004 90005 90002 90003 BEST PRICE 789 USD FOR BANK PAYMENT ONLY — CONTACT US NOW! PAY BY BANK 90004 90005 90002 90003 ORDER 3 BOXES, GET 450 USD (739 USD PER BOX) DICSOUNT NOW! 90004 90005 90002 90003 You can also check 10 vials here (click) 90004 90005 90018 Basic information on Laennec injections.90019 90002 90003 Official manufacturer 90004: JBP Co Ltd, Japan 90005 90002 90003 Active ingredient: 90004 human placenta hydrolysate. 90005 90002 90003 Start sales 90004: in Japan after clinical trials (conducted throughout the Japan in 124 cases) of Laennec in 1979, July. 90005 90002 90003 Official Code 90004 in Japan: 3259601A1024 90005 90002 Laennec is registered in USA, South Korea, China, Russia and NIS countries officially. 90005 90002 Clinically significant adverse reactions and 90003 Contraindications 90004: allergic reactions are possible 90005 90018 Clinical studies of Laennec: regarding medical effects.90019 90002 As a result of clinical trials conducted throughout Japan, positive effects on blood counts such as GOT and GPT were recognized — laennec was used in a number of liver and lung diseases, showing high regeneration and recovery effects. Studies were conducted at 95% intervals, for a more accurate effect, placebo tests was applied to achieve more accurate results. Side effects identified during the tests include allergies in 3.7% of patients. In less than one percent, itching and numbness were observed, but a clear connection between the injection and these symptoms has not been scientifically established.It is highly not recommended to use the drug during lactation and pregnancy. 90005 90002 Laennec appears in a variety of publications and scientific studies of medical subjects in Japan. The medical effect of Laenneca in the treatment of the liver was investigated by the doctor Ueda Hideo in his research Acta hepatologica Japonica Vol.15 (上 田英雄 肝 臓, vol.15 162 1974 (click here to follow) the positive effects of applying Laennec during clinical trials are shown. Dr. Sakamoto Koji (坂 本 浩 二) in his research on anti-age therapy and treatment of diseases of internal organs using cell regeneration in the University of Tokyo Medical Journal (東京 医科大学 雑 誌) pays special and deep attention to detailed clinical research on side effects before launching Laennec drug in Japan — in the issue of 東京 医科大学 雑 誌, vol.33,271 (1975) as well as 東京 医科大学 雑 誌, vol.31,829 (1973) and in東京 医科大学 雑 誌, vol.32,351 (1974).90005 90018 Dosage and administration of Laennec 90019 90002 Dosage: In chronic recurrent herpes and atopic dermatitis, the drug is injected via IV: 10 ml (560 mg of placental hydrolyzate) of the medicine (5 vials) are dissolved in 250-500 ml of 5% dextrose solution or saline and injected through the ulnar vein for 1.5 -2 h. Injections are carried out 3 times a week with an interval of 2 days. The course of treatment 10 injections. 90005 90002 90005 90002 In chronic liver diseases (steatohepatitis / alcoholic, metabolic, and mixed etiology /), the drug is administered intramuscularly at 2 ml / day (112 mg of placental hydrolyzate).Depending on the severity of the disease, the frequency of injections can be increased up to 2-3 times (6 ml) / day. The drug can be injected via IV: 10 ml (560 mg of placentae hydrolyzate) of the drug (5 ampoules) are dissolved in 250-500 ml of 5% dextrose solution or saline and injected through the ulnar vein for 1.5-2 hours. Injections are carried out daily. The course of treatment is 2-3 weeks. 90005 90018 How to identify genuine Japanese Laennec? 90019 90002 BEWARE OF KOREAN AND CHINESE FAKE PRODUCTS! It is very important to identify original product from Chinese and Korean fake copies.Orignal product is shipped only from Japan (from hospital), and never sold on domestic market, as it is a violation of Japan Law. 90005 90002 PLEASE PAY ATTENTION! 90005 90062 90063 Expiration date is less then 1 year (about 9-10 monhs). One box of 50 vials is for 5-6 month course. Apply one vial every 2 days for 2 months, then repeat in 1 — 1,5 months. 90064 90063 Product is shipped directly from Japan. 90064 90063 ORIGINAL JAPANESE PACKAGE.MADE IN JAPAN — KURUME PLANT. 90064 90063 90003 Expiration date is 1 year. Laennec manufactured in Japan differs from Korean laennec, it contains natural components, has better effect but it’s shelf life is 1 year. 90004 90064 90063 WE SHIP IN about 5-7 business days after the order. 90064 90063 We ship 50 vials and 10 vials in original package. 90064 90077 90078 Laennec from Japan: Dummy or Effective medicine? 90079 90002 More and more often, clients write us different questions about Laennec.How to buy a original Japanese Laennec, how to distinguish a fake and original product and, especially recently, whether Laennec will be effective in case of his or that disease. Customers keep asking if it be effective in treating cancer, oncology, stroke, kidney failure, diabetes and so on. A list of questions about the efficacy of Laennec from Japan in this or that disease can be continued on and on. Where do you, dear customers, take these data (about the potential effectiveness of the Laennec in case of oncology, etc.) ?. We will do our best to clarify the situation once and for all. 90005 90078 What Laennec is effective for? 90079 90002 Please, remember, the Japanese Laennec is effective for liver diseases, including hepatitis (but severe case requires additional treatment and other drugs), for skin diseases (including psoriasis, except for severe cases), as well as for the purpose of rejuvenating and antiaging therapy. The last item is not certified by medical supervisory authorities in number of countries, but it has been fully proved and confirmed in Japan and the USA.The efficacy of placental preparations has been also proven in Korea, where some of JBP products are produced. In Japan laennec is also applied for skin tightening and general cellular anti-aging therapy. 90005 90078 How to buy genuine Laennec from Japan? 90079 90002 Japanese-made Laennec can be purchased only in Japan. Neither in China, nor in the Philippines or in Thailand, you can not buy it! And even in Japan there are fakes, when they are sold from companies without a license or on net auctions like Ebay.On this product page, there is a complete guide on how to distinguish the original drug and buy real, Japanese, Japanese-manufactured goods. Customers sent us photos of goods purchased in other countries — ampoules have different lengths, shape, heterogeneous colour etc. Prints on the packaging are dirty, leaving stains and marks. But even this is not the main thing though a sufficient one. There is a simple and reliable way to distinguish a true Laennec from Japan. 90005 90078 How to identify genuine Laennec from Japan? 90079 90002 Pay attention to the packaging and the ampoules.On the packaging there is a unique three-dimensional volumetric code, which is hard enough to make and almost impossible to copy. Furthermore, on each ampoule of the Laennec there are two long numeric codes. These two codes are special labeling as required by the Japanese Medicines Act dated year 2008. The upper code is the sales lot code, the lower code is the code of the batch of pharmaceutical raw materials used for production. That is, everything is simple enough — one code is responsible for the sale, the second for the manufacture.90005 90078 How to apply Laennec in right way? 90079 90002 Applying the drug should be carried out strictly under the supervision of a specialist or doctor. Base dosages can be found on this page. The drug can be used intramuscularly, intravenously and for mesotherapy. Pay attention, if there are allergic reactions or strange / uncomfortable sensations, the application of the Laennec should be stopped immediately. 90005 90018 Articles about Laennec 90019 90002 You may be interested to check the following articles related to laennec from our blog section: 90005 90002 90005 90002 90005 90002 HOW TO IDENTIFY ORIGINAL PRODUCT? 90005 90002 90109 1.Original JBP package for domestic market. 90110 90005 90002 90005 90002 90115 90005 90002 2. Made in Japan marking on the side of original package. ( «Manufactured and Distributed by JBP Japan»). 90005 90002 90120 90005 90002 3. Expiry date and bar code. At the bottom there is a serial number of product. Specific 3D bar code with series and number (on the picture old code is shown, we always ship goods with 8-9 months ‘expiry date that is enought for full course.Box has pharma serial number and sales lot serial nuber (japanese control system). We covered series for privacy reasons. 90005 90002 90125 90005 90002 4. Ampoules of correct shape with serial number and bar code on every vial. 90005 90002 90130 90005 90002 90003 To protect privacy of our distributor we have hidden bar codes and serial number! 90004 90005 90002 5. For all laennec with expiration date of 2019.07 and further there is additional sticker added to package for protection reasons, as showm below.90005 90002 90139 90005 90002 WHITENING, ANTI-AGING MOISTURIZING 90005 90002 90005 90002 90003 100% human Placenta Laennec (Original, Directly from Japan — from Maker and official distributor). 90004 90005 90002 90005 90002 90005 90002 90003 ALSO CHECK LAENNEC — 50 pcs — FOLLOW THE LINK 90004 90005 90002 90003 90159 90004 90005 90002 90003 LAENNEC — 50 pcs 90004 90005 90002 90005 90002 Effective for: 90005 90002 90005 90002 1.general fatigue 2.Stiffness of shoulders 3.Astma 4.Urticaria (hives) 5.Migraine 6. Prostatic hypertrophy 7.Menopause 8. Andropause (male enopause) 9. Dysmenorrhea 10.Ovarian Dysfunction 11.Frigidity 12.Oligogalactia 13. Gestational toxicosis 14.Chronic constipation 15. Gastroptosis 16.Gastric ulcer 17. Stomack cancer 18.Dyspepsia 19.Hypertension 20.Hypotension 21.Neuralgia 22.Neurosis 23. Hepatitis 24. Liver cirrhosis 25. Retinal pigmenttary dystrophy 26.Cataract 27.Iritis 29. Hearing loss 30.Tinnitus 31.Anemia 32.raynaud disease 33.lupus 34.Nocturnal Enurosis (bed-wetting) 35.Eczema 36.Melasma 37.Skin Allergy 38.Skin cancer 39.Keloid scar. 90005 90002 90005 90002 100% HUMAN PLACENTA EXTRACT 90005 90002 90005 90002 The fact that 100% Human Placenta Extract was proven to be beneficial to human body. Japanese government had no doubts in acknowledging it as an alternative medicine for anti-aging program. Even the American Food and Drug Agency did conform with the Japanese Government on this issue.Knowing the high medical standard of the Japanese government, 100% HPE has meticulously pass its standards. Undoubtful and sure, most of the modern beauty enthusiasts has been using 100% for ANTI-AGING, WHITENING and MOSTURIZING agent. Which is, BETTER than BOTOX. It also harmless and more compatible for humans to use rather than from four legged animals. And take note, 100% HPE is not only for anti-aging programs! It has also many benefits to offer for human. The following mentioned below are just some of the ailment that can be treated by 100% HPE.90005 90002 90005 90002 Certified in Japan, Korea, USA, this is currently the most reliable and effective injectable drug. 90005 90002 90005 90002 90003 Official Japanese Certificate. 90004 90005 90002 90193 90005 .90000 LAENNEC | 주식회사 일본 생물 제제 90001 90002 Laennec is the ethical drug manufactured with JBP’s unique technologies. 90003 90004 Laennec is the ethical drug manufactured with JBP’s unique technologies for effective extraction of variety of growth factors, cytokines, and other physiologically active substances from the human placenta. For instance, HGF (hepatocyte growth factor) promotes the proliferation of hepatic parenchymal cells for recovery of a damaged liver.Our product safety is ensured by the most rigid safety measures among existing scientific standards. 90005 90004 90007 Warning: 90008 90007 As the LAENNEC Injection is an ethical drug, JBP has never sold it on Internet. 90008 90005 90012 90013 90014 90015 90016 90015 Ingredients 90016 90015 Content 90016 90015 Remarks 90016 90023 90014 90015 Active ingredient 90016 90015 Water-soluble substance of a product of enzymatic human placenta 90016 90015 112 mg 90016 90015 Ingredient extracted from human placenta 90016 90023 90014 90035 Inactive ingredients 90016 90015 Pepsin 90016 90015 Trace 90016 90015 Gastric mucosal extract (pig) 90016 90023 90014 90015 Lactose 90016 90015 0.6 mg 90016 90015 — 90016 90023 90014 90015 pH adjuster 90016 90015 q.s. 90016 90015 — 90016 90023 90060 90061 90004 90007 Description 90064 90008 This product is a light yellow-brown or yellow-brown clear liquid with a distinctive odor. The pH level ranges from 5.5 to 6.5 and the osmotic pressure ratio (to physiological saline) is approximately one. 90005 90004 90007 Indications 90064 90008 Improvement of hepatic function in chronic hepatic disease.90005 90004 90007 Dosage and administration 90064 90008 The normal adult dose is a 2 ml subcutaneous or intramuscular injection once daily. According to symptoms, the dose can be increased to 2 or 3 times daily. 90005 90004 90007 Packaging 90064 90008 2 ml 50 ampoules 90005 90002 Cautions for use ** 90007 90008 90003 90004 90007 1. Careful Administration 90064 90008 LAENNEC should be administrated with care in patients predisposed to allergies. 90005 90004 90007 2. Important Basic Cautions 90064 90008 This product is manufactured from the extract of human placenta delivered full-term in Japan.In order to screen each donor, a complete medical history, interviewing such as a history of travel and serologic testing for viruses, bacteria and infection are performed, after nucleic-acid testing (NAT) to meet with requirements for HBV-DNA, HCV- RNA and HIV-1-RNA is carried out. In addition, it has been confirmed that high-pressure steam sterilization for 20 minutes at 121 ° C during the manufacturing process is effective in inactivating various viruses such as HIV etc. Furthermore, although in the product test, the nucleic-acid test meets with requirements for HBV-DNA, HCV-RNA, HIV-1-RNA, HTLV-DNA, and parvovirus B19-DNA, patients should be made aware of the following points during administration: To date, the transmission of infection, such as variant Creutzfeldt-Jakob disease (vCJD), by administration of this product in Japan or other countries has not been reported.However, although safety measures are taken to prevent infection during the manufacturing process, it is theoretically impossible to fully eliminate the risks of infection transmission originating in a human placenta used as raw material. While safety measures during the manufacturing process to prevent infection, as well as confirmation of the necessity of treatment for the disease before administration are carried out, doctors should explain to patients and try to have them understand that when human placenta is used as the raw material of a product, the risk of infection can not be fully ruled out.90005 90004 90007 3. Drug Interactions 90064 90008 When this product is directly mixed with a strong base preparation of pH 8.5 or more, attenuation of pharmacological activity has been reported. 90064 No coadministration with this product resulting in the enhancement or attenuation of the pharmacological effect of this product or concomitant drugs, appearance of adverse reactions, or aggravation of disease has been reported. 90005 90004 Adverse reactions or patients who were suspected to have suffered adverse reactions to this product were reported in a total of 10 (3.7%) of the 273 patients selected for safety evaluation in the clinical study performed during implementation of reevaluation of the drug efficacy. The most frequently observed adverse reactions were injection site pain in 7 patients (2.6%), hypersensitivity (such as rash, fever, and itching) in 1 patient (0.4%), injection site indurations in 1 patient (0.4%), and gynaecomastia in 1 patient (0.4%). The causal relationship between gynaecomastia and this product is unknown. 90064 No abnormal changes in laboratory values ​​were observed.90104 1) 90064 90106 • Clinically significant adverse reactions 90064 ** Shock (incidence unknown): 90064 Since this product is a protein / amino acid preparation derived from human tissue, this product may cause a shock. If any signs of abnormality are observed, the drug should be discontinued immediately, appropriate measures should be taken and the condition should be monitored fully. 90064 • Other adverse reactions (in descending order of occurrence) 90005 90111 90013 90014 90015 Injection site pain 90016 90015 2.56% 90016 90023 90014 90015 Sensitivity (rash, fever, itching etc.) 90016 90015 0.37% 90016 90023 90014 90015 Injection site indurations 90016 90015 0.37% 90016 90023 90014 90015 Gynaecomastia 90016 90015 0.37% 90016 90023 90060 90061 90004 90007 4. Use in the Elderly 90064 90008 From clinical data and present use, no particular caution is needed in the administration of this product to the elderly.However, since elderly patients often have reduced physiological function, it should be administrated with care. 90005 90004 90007 5. Use during Pregnancy. Delivery or Lactation 90064 90008 In reproductive development toxicity experiments on animals, including teratogenicity, this product can be considered not to have such toxicity. 90104 2) 90106 90005 90004 90007 6. Pediatric use 90064 90008 The safety of this product in premature infants, newborns, infants, toddlers or children has not been established due to insufficient clinical data.90005 90004 90007 7. Overdosage 90064 90008 Overdosage of this product and the resulting efficacy or safety have not been established (Due to insufficient clinical data). 90005 90004 90007 8. Precautions for Use 90064 90008 Injection site: 90064 In order to avoid any effect on tissue or nerves, the product should be injected subcutaneously or intramuscularly taking the following precautions: 90064 a) For the injection site, to avoid nerve pathways, it should be administrated with care.90064 b) In the case of repeated injections, avoid injecting into the same site by alternating on the left and right side etc. 90064 c) If intense pain or regurgitation of blood is observed, the needle should be removed immediately, and injected into a different site. 90064 Opening the ampoule: 90064 When opening the ampoule, it is preferable to wipe the part to be cut with an ethanol sponge before opening it. 90005 90004 90005 90002 Pharmacokinetics 90003 90004 The bioactive ingredients of LAENNEC are extracted from human placenta, and the primary pharmacological effects of this product can not necessarily be attributed to a single substance or ingredient.Therefore, evaluation of the pharmacokinetics (absorption, distribution, metabolism, and excretion) of this product has not been established. 90005 90004 90005 90002 Clinical studies 90003 90004 90007 1. Double blind comparison to chronic hepatitis and hepatic cirrhosis 90104 1) 90064 90106 90008 In a double-blind crossover study of 124 patients in Japan on the effects of this product on chronic hepatitis and hepatic cirrhosis, administration of this product improved serum transaminase (GOT, GPT) levels significantly (see figures below).90005 90004 Efficacy to GOT 90064 90005 90004 Efficacy to GPT 90064 90005 90004 Summary of drug-efficacy 90064 [(A) Items having a tendence to decrease or increase significantly by Laennec] 90005 90004 Data on pharmacological reevaluation 90064 Summary of drug-efficacy 90064 [(B) Items having a tendence to decrease or increase significantly by Placebo] 90005 90004 90007 2. Action on HCV-RNA levels 90104 3) 90064 90106 90008 Twenty subjects of two-agent combination therapy only with Stronger Neo-Minophagen C and Acelart were performed in the past and negativation neither of C100-3 antibody nor HCV-RNA was admitted in them.In three-agent combination therapy with Laennec added, two negative cases of serum HCV-RNA levels were admitted. 90005 90004 90005 90002 Pharmacology 90003 90004 90007 1. Stimulatory effects of hepatic reproduction 90104 4), 5) 90064 90106 90008 After 70% of livers in healthy rats was resected, time comparisons of liver weight to the control groups resulted in significant stimulation of hepatic reproduction in the Laennec groups. 90005 90004 90007 2. Stimulatory effects of cellular DNA synthesis 90104 4) 90064 90106 90008 Compared to control groups, in vivo experimental system using primary culture rat hepatocytes, the DNA-synthesis accelerator activity was observed in 2 μL / ml-administrated groups.That accelerator activity was equivalent to 10 pM of rHGF. The liver tissue in vivo experimental system using rats with acute hepatitis by ANIT was stained and the result of evaluation of the rate of hepatocyte nucleus in DNA synthesis period showed significant accelerator of DNA synthesis compared to the control groups. 90005 90004 90007 3. Inhibitory effects of experimental liver injury 90104 4), 6) 90064 90106 90008 Compared to control groups, in vivo experimental system using rats with acute hepatitis by ANIT, the liver cytosolic enzymes in serum (GPT, ALP, LAP and g -GTP) and the bilirubin levels significantly degreased in the Laennec groups.90064 In addition, compared to control groups, in vivo experimental system using rats with acute hepatitis and chronic hepatitis by CCI4, the liver cytosolic enzymes in serum (GPT, GOT) significantly degreased and histopathologically improved liver disorder in the Laennec groups. 90005 90004 90007 4. Anti-fatty liver action 90104 7) 90064 90106 90008 A 5-day subcutaneous injection of 1.2 ml / kg of this product in rats suffering from acute hepatic disorder with CCI4 resulted in a significant decrease in hepatic weight to body weight as compared with the control groups.Furthermore, total hepatic lipids and total hepatic cholesterol decreased significantly in the 3.6 ml / kg dose groups, and hepatohistological findings to support such results were seen and the body weight was realized. 90064 After pretreatment of acute hepatic disorder with CCI4, there were no significant differences with regards to biochemical findings between the control groups and when 5-day repeated, subcutaneous administration of 1.2 ml / kg of this product was performed. However, in the 3.6-ml / kg dose groups, maintenance of lobular structure was better than the control groups with regards to hepatohistological findings.90005 90004 90007 5. Absorption accelerated activity on interstitial connective tissue 90104 8) 90064 90106 90008 This product exhibited inhibitory action of fibroplasias in rat liver due to 12-week repeated administration of CCI4, and it was confirmed histologically that once multiplied, interstitial connective tissues were absorbed. 90005 90004 90005 90002 Physicochemistry 90003 90004 This product is human-placental extract, and contains various biological active substances. However, the active ingredients of this agent can not be specified as a single substance or several sorts of substances.90005 90004 90005 90002 Precautions for handling * 90003 90004 This product corresponds to a specialized biological product. Therefore, when this product is administrated, the product name, manufacturing No., date of administration (or prescription), name and address of patients should be reported and stored for at least 20 years in accordance with the order issued by the Japanese Ministry of Health, Labour and Welfare. This product should be used with attention to the point that the indication of this product is «improvement of hepatic function in chronic liver disease».90005 90004 90005 90004 90007 References 90064 90008 1) Ueda H. et al .: Kanzo (Liver), vol.15, 162, 1974 90064 2) Taniguchi H. et al .: data on file in Japan Bio Products Co. Ltd., 1985-1991 90064 3) Takami T .: Kiso to Rinsho, vol.30, 3549, 1996. 90064 4) Liu K. et al .: Yakuri to Rinsho, vol.5, 2187, 1995 90064 5) Sakamoto K . et al .: Journal of Tokyo Medical University, vol.33, 271, 1975 90064 6) Nakayama S. et al .: Folia Pharmacologica Japonica, vol.94, 289, 1989 90064 7) Sakamoto K. et al.: Journal of Tokyo Medical University, vol.31, 829, 1973 90005 .